In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against pseudomonas aeruginosa

28Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Relebactam is a novel class A/C -lactamase inhibitor that restores imipenem in vitro activity against multidrug-resistant and carbapenem-nonsusceptible Pseudomonas aeruginosa. Time-kill analyses were performed to evaluate the potential role of imipenem-relebactam in combination with amikacin or colistin against P. aeruginosa. Ten clinical P. aeruginosa isolates (9 imipenem nonsusceptible) with imipenem-relebactam MICs ranging from 1/4 to 8/4 g/ml were included. The isolates had varied susceptibilities to imipenem (1 to 32 g/ml), amikacin (4 to 128 g/ml), and colistin (0.5 to 1 g/ml). Duplicate 24-h time-kill studies were conducted using the average steady-state concentrations (Cssavg) observed after the administration of imipenem-relebactam at 500 mg/250 mg every 6 hours (q6h) alone and in combination with the Cssavg of 25 mg/kg of body weight/day amikacin and 360 mg/day colistin in humans. Imipenem-relebactam alone resulted in 24-h bacterial densities of 2.93 0.38, 1.67 0.29, 0.38 0.96, and 0.15 0.65 log10 CFU/ml at imipenem-relebactam MICs of 1/4, 2/4, 4/4, and 8/4 g/ml, respectively. No synergy was demonstrated against the single imipenem-susceptible isolate. Against the imipenem-nonsusceptible isolates (n 9), imipenem-relebactam combined with amikacin resulted in synergy (2.61 1.50 log10 CFU/ml) against all amikacin-susceptible isolates and in two of three amikacin-intermediate (i.e., MIC, 32 g/ml) isolates (2.06 0.19 log10 CFU/ ml). Synergy with amikacin was not observed when the amikacin MIC was 32 g/ ml. Imipenem-relebactam combined with colistin demonstrated synergy in eight out of the nine imipenem-resistant isolates (3.17 1.00 log10 CFU/ml). Against these 10 P. aeruginosa isolates, imipenem-relebactam combined with either amikacin or colistin resulted in synergistic activity against the majority of strains. Further studies evaluating combination therapy with imipenem-relebactam are warranted.

Cite

CITATION STYLE

APA

Asempa, T. E., Nicolau, D. P., & Kuti, J. L. (2019). In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 63(9). https://doi.org/10.1128/AAC.00997-19

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free